All In Biotech

Drug Trial Radar · NCT05298046

Study of TAVO101 in Healthy Volunteers

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAVO101 in Adult Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

May 11, 2022

Primary completion

Jun 1, 2024

Study completion Sep 30, 2024

Sponsor

Lead sponsor
Tavotek BiotherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, single ascending dose study designed to investigate TAVO101, administered as an IV infusion in healthy subjects. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAVO101.

Conditions

  • Healthy Subjects

Interventions

  • Experimental: TAVO101Drug

    TAVO101 single ascending dose IV infusion.

  • Other: PlaceboOther

    Placebo single ascending dose IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The severity of adverse effects according to the National Cancer Institute's Common Terminology Criteria for AEs, Version 5.0 [Time Frame: Day 1 through Day 196]Time frame: 196 days
  2. Changes in vital signs including oral temperature or tympanic temperature (C°) [Time Frame: Day 1 through Day 196]Time frame: 196 days
  3. Changes in vital signs including respiratory rate (breaths per minute) [Time Frame: Day 1 through Day 196]Time frame: 196 days
  4. Changes in vital signs including systolic and diastolic blood pressure (mmHg) [Time Frame: Day 1 through Day 196]Time frame: 196 days
  5. Changes in vital signs including pulse rate (beats per minute) [Time Frame: Day 1 through Day 196]Time frame: 196 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research Pty Ltd

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.